Vascular protection from atherosclerosis: potential of calcium antagonists

W W Parmley1

  • 1Division of Cardiology, University of California School of Medicine, San Francisco 94143.

Insights

Calcium plays a key role in atherosclerosis development. Calcium channel blockers, like nifedipine, verapamil, and diltiazem, show promise in preventing atherosclerosis in animal models, suggesting potential benefits for hypertension therapy.

Area of Science:

  • Cardiovascular Science
  • Pharmacology
  • Biomedical Research

Background:

  • Atherosclerosis involves complex processes, with calcium playing a critical role.
  • Calcium uptake by cells is implicated in lesion development.
  • Existing research suggests calcium's central role in atherogenesis.

Purpose of the Study:

  • To investigate the role of calcium in atherosclerosis.
  • To evaluate the antiatherosclerotic effects of calcium antagonists in experimental models.
  • To explore the potential of calcium antagonists in antihypertensive therapy.

Main Methods:

  • Review of experimental models of atherosclerosis.
  • Analysis of the effects of various calcium antagonists (nifedipine, verapamil, diltiazem).
  • Focus on the mechanism of blocking intracellular calcium influx.

Main Results:

  • Interventions inhibiting cellular calcium uptake retarded lesion development in experimental atherosclerosis.
  • Calcium antagonists demonstrated protective effects against atherosclerosis in animal models.
  • A common mechanism of action for these drugs is blocking intracellular calcium influx.

Conclusions:

  • Calcium is critical in the pathogenesis of atherosclerosis.
  • Calcium antagonists possess antiatherosclerotic properties in experimental settings.
  • Further clinical trials are needed to confirm the relevance of these findings for human antihypertensive therapy selection.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...